BioSpace News Archive

Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design new medicines, today announced the publication of new research findings in Science Advances co-authored by Casma scientists, along with Oliver Florey, Ph.D., of the Brabraham Institute, and Casma scientific co-founder Andrea Ballabio, M.D., of the Telethon Institute of Genetics and Medicine.

Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials

Magenta Therapeutics, Inc. today announced the appointment of Jeffrey Humphrey, M.D., as the company’s Chief Medical Officer where he will be responsible for all clinical development and regulatory initiatives.

IVERIC bio, Inc. reported that on October 1, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to eight newly-hired, non-executive employees.

VBI Vaccines Inc., a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, announced that members of the management team will participate in analyst-led fireside chats at the following upcoming investor conferences.

Imperative Care, Inc. announced today that the first patient has been enrolled in the Imperative Trial.

BioSig Technologies, Inc. announced that an article titled, “Evaluation of a novel cardiac signal processing system for electrophysiology procedures: the PURE EP 2.0 study” has been published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access as of September 23, 2021, via the Wiley Online Library.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of a post-hoc analysis from the N-MOmentum phase 2/3 pivotal trial of UPLIZNA, which highlights a sustained effect on attack risk with no new safety signals in people with NMOSD who received the treatment for four or more years.

ImmunityBio, Inc. (NASDAQ: IBRX), today announced the Lung Cancer Master Protocol (Lung-MAP) public-private partnership—which includes the National Cancer Institute (NCI), the National Clinical Trials Network (NCTN) Cooperative Groups (SWOG, ECOG-ACRIN, Alliance, and NRG), Friends of Cancer Research, and the Foundation for the National Institutes of Health (FNIH)—will study the company’s IL-15 receptor superagonist complex, N-803 (Anktiva), in the Lung-MAP trial.

CrestOptics S.p.A., a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and diagnostic applications, announced the launch of DeepSIM, a super resolution module designed to enhance the imaging capabilities of confocal microscope systems.